Relation of Chemerin to Insulin Resistance, Inflammation and Obesity in Type II Egyptian Diabetics

Abstract

Chemerin is an adipokine that regulates adipogenesis and adipocyte metabolism. It may mediate a link between obesity, inflammation, insulin resistance, type 2 diabetes mellitus and cardiovascular disease. The aim of the present work is to investigate the causal relationship between serum chemerin, insulin resistance and inflammatory markers in lean and obese type II Egyptian diabetics. This study included 120 subjects, classified into the following groups (each thirty): GI: lean controls, GII: lean diabetics, GIII: Obese controls and GIV: Obese diabetics. The following biochemical parameters were estimated in this study: serum chemerin, fasting and postprandial plasma glucose (FPG & PPPG), glycated hemoglobin (HbA1c), serum insulin, lipids profile [total cholesterol (TC), triacylglycerols (TAGs), high density lipoprotein-cholesterol (HDL-C) and low density lipoprotein-cholesterol (LDL-C)], as well as tumor necrosis factor-α (TNF-α) and interleukin 6 (IL-6). In addition, body mass index (BMI), HOMA-IR (homeostasis model assessment for insulin restistance) and HOMA-β (homeostasis model assessment of β-cell function) were calculated and blood pressure was measured. Results revealed that serum chemerin levels were significantly increased in lean and obese type 2 diabetic patients compared to their controls and in obese subjects compared with Abstract iv lean normal controls. Chemerin showed higher results in obese than lean subjects. Serum chemerin levels were also positively correlated with age, BMI, FPG & PPPG, serum insulin, HOMA-IR, TC, TAGs, LDL-C,TNF-α and IL-6. Moreover, a negative correlation was found between serum chemerin level, HOMA-β and HDL-C. However, no significant correlation was observed between serum chemerin levels and sex. In conclusion, serum chemerin is associated with insulin resistance, inflammation and obesity in type II Egyptian diabetics